PMV Pharmaceuticals is offering common stock, pre-funded warrants and common stock warrants within a shelf registration permitting up to $200,000,000 in aggregate sales. Net proceeds are intended for late-stage rezatapopt development, regulatory submissions, commercialization preparation, Working Capital and general corporate purposes, giving investors a clear view of the planned funding priorities.

Key Highlights

  • The company’s authorized capital includes 1,000,000,000 common shares and 5,000,000 preferred shares.
  • Net proceeds are intended for rezatapopt development, regulatory submission, commercialization preparation, working capital and general corporate purposes.
  • PMV Pharmaceuticals is offering common stock, pre-funded warrants and common stock warrants.

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is offering common stock, pre-funded warrants and common stock warrants through a shelf registration permitting aggregate securities sales of up to $200,000,000. Net proceeds are intended to support late-stage clinical development of rezatapopt, regulatory submission and commercialization preparation activities, along with working capital and general corporate purposes. Management will retain broad discretion over allocating the proceeds.

PMV Sets Offering Framework and Equity Capacity

PMV Pharmaceuticals had 53,460,432 common shares outstanding as of June 30, 2026. The exclusions also include 3,185,748 common shares reserved under the 2020 Equity Incentive Plan and 1,033,530 shares reserved under the 2020 Employee Stock Purchase Plan. Those figures exclude automatic increases in the respective plan reserves. PMV’s authorized capital consists of 1,000,000,000 common shares and 5,000,000 preferred shares, each with a Par Value of $0.00001 per share. Historical net tangible Book Value stood at $1.34 per share as of June 30, 2026. The common stock warrants and pre-funded warrants have no established public trading market, and PMV does not intend to seek exchange or recognized trading-system listings for them.

Peers Moving on This News